• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗抑郁药治疗 COVID-19：系统评价。

Antidepressants for COVID-19: A systematic review.

机构信息

The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.

Unit of Psychiatry, Department of Public Health and Medicinal Administration, & Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, China; Centre for Cognitive and Brain Sciences, University of Macau, Macau SAR, China; Institute of Advanced Studies in Humanities and Social Sciences, University of Macau, Macau SAR, China.

出版信息

J Affect Disord. 2022 Jun 15;307:108-114. doi: 10.1016/j.jad.2022.03.059. Epub 2022 Mar 23.

DOI:10.1016/j.jad.2022.03.059
PMID:35339571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8941844/
Abstract

OBJECTIVE

To systematically examine the efficacy and safety of antidepressants for the treatment of coronavirus disease 2019 (COVID-19).

METHODS

A systematic search was performed independently by two researchers based on Chinese Journal Net, WanFang, PsycINFO, Cochrane Library, PubMed, and EMBASE.

RESULTS

Seven studies (n = 92,947) including three retrospective studies (n = 91,083), two randomized clinical trials (RCTs, n = 1649), two prospective cohort study (n = 215) involving (n = 92,947) patients with COVID-19 were examined. For RCTs, fluvoxamine outperformed placebo in reducing clinical deterioration and hospitalisation for COVID-19 patients. For retrospective studies, antidepressants (2 studies) and fluoxetine (1 study) possibly reduced the risk of mortality in patients with COVID-19. Results from two remaining studies supported the superiority of fluvoxamine in reducing risk of mortality in COVID-19 patients. The two RCTs that examined the safety of fluvoxamine for COVID-19 patients found inconsistent results but no significant group differences in the dropout rate.

CONCLUSION

This systematic review found emerging evidence for fluvoxamine in reducing the risk of mortality and hospitalisation in COVID-19 patients, but inconsistent evidence for the safety of fluvoxamine in COVID-19 patients. More studies are needed to determine the efficacy and safety of antidepressants for the treatment of COVID-19.

摘要

目的

系统评估抗抑郁药治疗 2019 冠状病毒病（COVID-19）的疗效和安全性。

方法

两位研究者独立基于中国知网、万方、PsycINFO、 Cochrane Library、PubMed 和 EMBASE 进行系统检索。

结果

共纳入 7 项研究（n=92947），包括 3 项回顾性研究（n=91083）、2 项随机对照试验（RCT，n=1649）和 2 项前瞻性队列研究（n=215），共纳入 92947 例 COVID-19 患者。对于 RCT 研究，氟伏沙明在降低 COVID-19 患者临床恶化和住院风险方面优于安慰剂。对于回顾性研究，抗抑郁药（2 项研究）和氟西汀（1 项研究）可能降低 COVID-19 患者的死亡率。另外 2 项研究的结果支持氟伏沙明降低 COVID-19 患者死亡率的优势。两项评估氟伏沙明治疗 COVID-19 患者安全性的 RCT 研究得出了不一致的结果，但两组间的脱落率无显著差异。

结论

本系统评价发现氟伏沙明在降低 COVID-19 患者的死亡率和住院风险方面有新的证据，但氟伏沙明治疗 COVID-19 患者的安全性证据不一致。需要更多的研究来确定抗抑郁药治疗 COVID-19 的疗效和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/8941844/c499f8acae18/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/8941844/4e16dc8e019c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/8941844/c499f8acae18/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/8941844/4e16dc8e019c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8b/8941844/c499f8acae18/gr2_lrg.jpg

相似文献

1
Antidepressants for COVID-19: A systematic review.抗抑郁药治疗 COVID-19：系统评价。
J Affect Disord. 2022 Jun 15;307:108-114. doi: 10.1016/j.jad.2022.03.059. Epub 2022 Mar 23.
2
Fluvoxamine for the treatment of COVID-19.氟伏沙明治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Sep 14;9(9):CD015391. doi: 10.1002/14651858.CD015391.
3
Antidepressants for insomnia in adults.用于治疗成人失眠的抗抑郁药。
Cochrane Database Syst Rev. 2018 May 14;5(5):CD010753. doi: 10.1002/14651858.CD010753.pub2.
4
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.21 种抗抑郁药治疗成人重度抑郁症的急性治疗的疗效和可接受性比较：系统评价和网络荟萃分析。
Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21.
5
WITHDRAWN: Antidepressants for depression in medical illness.撤回：用于治疗躯体疾病伴发抑郁症的抗抑郁药。
Cochrane Database Syst Rev. 2007 Jul 18;2000(4):CD001312. doi: 10.1002/14651858.CD001312.pub2.
6
Antidepressants for the treatment of people with co-occurring depression and alcohol dependence.用于治疗同时患有抑郁症和酒精依赖症患者的抗抑郁药。
Cochrane Database Syst Rev. 2018 Apr 24;4(4):CD008581. doi: 10.1002/14651858.CD008581.pub2.
7
Antidepressants for the treatment of depression in people with cancer.用于治疗癌症患者抑郁症的抗抑郁药。
Cochrane Database Syst Rev. 2018 Apr 23;4(4):CD011006. doi: 10.1002/14651858.CD011006.pub3.
8
Antidepressants versus placebo for panic disorder in adults.成人惊恐障碍患者使用抗抑郁药与安慰剂的对照研究
Cochrane Database Syst Rev. 2018 Apr 5;4(4):CD010676. doi: 10.1002/14651858.CD010676.pub2.
9
Antidepressants for depression in medical illness.用于治疗躯体疾病伴发抑郁症的抗抑郁药。
Cochrane Database Syst Rev. 2000(4):CD001312. doi: 10.1002/14651858.CD001312.
10
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

引用本文的文献

1
Amitriptyline potently neutralizes distinct SARS-CoV-2 variants including D614G, Omicron BA.5, and Omicron XBB.1.阿米替林能有效中和包括D614G、奥密克戎BA.5和奥密克戎XBB.1在内的不同严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体。
Front Microbiol. 2025 Aug 4;16:1631947. doi: 10.3389/fmicb.2025.1631947. eCollection 2025.
2
Genetic analyses point to alterations in immune-related pathways underpinning the association between psychiatric disorders and COVID-19.基因分析表明，免疫相关通路的改变是精神疾病与新冠病毒病（COVID-19）之间关联的基础。
Mol Psychiatry. 2025 Jan;30(1):29-36. doi: 10.1038/s41380-024-02643-0. Epub 2024 Jul 3.
3

本文引用的文献

1
Mechanisms of action of fluvoxamine for COVID-19: a historical review.氟伏沙明治疗 COVID-19 的作用机制：历史回顾。
Mol Psychiatry. 2022 Apr;27(4):1898-1907. doi: 10.1038/s41380-021-01432-3. Epub 2022 Jan 7.
2
Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial.二甲双胍早期治疗对2019冠状病毒病患者急诊和住院风险的影响：TOGETHER随机平台临床试验
Lancet Reg Health Am. 2022 Feb;6:100142. doi: 10.1016/j.lana.2021.100142. Epub 2021 Dec 14.
3
Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective case-control study.
The Effect of Antidepressant Treatment on Neurocognitive Functions, Redox and Inflammatory Parameters in the Context of COVID-19.
抗抑郁治疗对新冠疫情背景下神经认知功能、氧化还原及炎症参数的影响
J Clin Med. 2023 Nov 12;12(22):7049. doi: 10.3390/jcm12227049.
4
Serotonin reduction in post-acute sequelae of viral infection.病毒感染后急性后遗症中的血清素减少。
Cell. 2023 Oct 26;186(22):4851-4867.e20. doi: 10.1016/j.cell.2023.09.013. Epub 2023 Oct 16.
5
Reports analysis of psychotropic drugs related adverse reactions in Australia and Poland during the COVID 19 pandemic.报告分析了 COVID-19 大流行期间澳大利亚和波兰与精神药物相关的不良反应。
Biomed Pharmacother. 2023 Jun;162:114681. doi: 10.1016/j.biopha.2023.114681. Epub 2023 Apr 7.
6
Initiation of antidepressants in patients infected with SARS-COV-2: Don't forget Caution for "Paradoxical" Anxiety/Jitteriness syndrome-Commentary: Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution.感染新型冠状病毒肺炎（SARS-CoV-2）患者中抗抑郁药的使用：勿忘警惕“矛盾性”焦虑/神经过敏综合征——评论：新型冠状病毒肺炎（COVID-19）感染中选择性5-羟色胺再摄取抑制剂的处方需谨慎。
Front Psychiatry. 2023 Mar 13;14:1095244. doi: 10.3389/fpsyt.2023.1095244. eCollection 2023.
7
Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19.选择性5-羟色胺再摄取抑制剂：对抗新冠病毒的新希望。
Front Pharmacol. 2022 Nov 30;13:1036093. doi: 10.3389/fphar.2022.1036093. eCollection 2022.
8
Factors associated with mortality in hospitalised, non-severe, older COVID-19 patients - the role of sarcopenia and frailty assessment.与住院非重症老年 COVID-19 患者死亡率相关的因素-肌肉减少症和衰弱评估的作用。
BMC Geriatr. 2022 Dec 7;22(1):941. doi: 10.1186/s12877-022-03571-w.
9
Higher benefit-risk ratio of COVID-19 vaccination in patients with schizophrenia and major depressive disorder versus patients with bipolar disorder when compared to controls.与对照组相比，精神分裂症和重度抑郁症患者接种新冠病毒疫苗的获益风险比高于双相情感障碍患者。
Am J Transl Res. 2022 Aug 15;14(8):5719-5729. eCollection 2022.
10
A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants.一株表达 ACE2 和 TMPRSS2 的新型工程化 A549 细胞系对 SARS-CoV-2，包括德尔塔和奥密克戎变异株高度易感。
Viruses. 2022 Jun 23;14(7):1369. doi: 10.3390/v14071369.
氟西汀的使用与 COVID-19 肺炎患者生存率的提高有关：一项回顾性病例对照研究。
Ideggyogy Sz. 2021 Nov 30;74(11-12):389-396. doi: 10.18071/isz.74.0389.
4
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.氟伏沙明治疗 SARS-CoV-2 感染的早期治疗：当前证据综述。
Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.
5
Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.COVID-19 患者处方选择性 5-羟色胺再摄取抑制剂抗抑郁药的死亡风险。
JAMA Netw Open. 2021 Nov 1;4(11):e2133090. doi: 10.1001/jamanetworkopen.2021.33090.
6
Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.氟伏沙明治疗 COVID-19 重症监护病房患者的安全性和有效性：一项开放标签、前瞻性队列研究，设有匹配对照。
Br J Clin Pharmacol. 2022 May;88(5):2065-2073. doi: 10.1111/bcp.15126. Epub 2021 Dec 1.
7
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.氟伏沙明早期治疗对 COVID-19 患者急诊和住院风险的影响：TOGETHER 随机、平台临床试验。
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
8
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial.阿奇霉素对比标准治疗用于轻至中度 COVID-19 患者（ATOMIC2）：一项开放标签、随机试验。
Lancet Respir Med. 2021 Oct;9(10):1130-1140. doi: 10.1016/S2213-2600(21)00263-0. Epub 2021 Jul 9.
9
Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy.能够降低 SARS-CoV-2 感染住院率和死亡率的药物：sigma-1 受体和自噬的可能作用。
Expert Opin Ther Targets. 2021 Jun;25(6):435-449. doi: 10.1080/14728222.2021.1952987. Epub 2021 Jul 15.
10
Suicide prevention and COVID-19.自杀预防与 COVID-19。
Asia Pac Psychiatry. 2021 Sep;13(3):e12482. doi: 10.1111/appy.12482. Epub 2021 Jun 11.